Abstract
This paper reviews the nonclinical reproductive toxicity testing of 15 drugs currently approved in the USA or Europe for the treatment of cancer. The list includes cytotoxic anti-tumour agents, small molecule inhibitors of pathways involved in neoplastic proliferation, monoclonal antibodies that target specific antigens expressed by neoplastic cells and supportive therapies used to counter the effects of chemotherapy. Most, but not all, drugs were tested for developmental or reproductive toxicity in animals prior to marketing and most were found to be embryotoxic or teratogenic. Because of the unmet need for comparative safety data on available cancer therapies for use by physicians when treating pregnant patients, at least embryofetal toxicity studies are now usually requested prior to marketing of new anti-cancer drugs, even when the pharmacological profile suggests likely side-effects on the embryo or fetus. Rats and rabbits are the preferred experimental species, but non-human primates have to be used for some biopharmaceuticals. Nonclinical study designs for anti-cancer drugs should be designed to allow the possibility of terminating the study once adverse effects have been demonstrated, without using the full number of animals specified in regulatory guidelines. All 15 drugs are currently labelled as being harmful to pregnancy, ether on the basis of animal data or documented hazards in humans. It is hoped that the forthcoming revision of the FDA drug labelling legislation will allow a better graduation of the relative risk between available anti-cancer therapies.
Keywords: Anti-cancer drugs, EMA, embryotoxicity, FDA, nonclinical safety testing, reproductive toxicity, teratogenicity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Volume: 17 Issue: 9
Author(s): Paul Barrow*Georg Schmitt
Affiliation:
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, 124 Grenzacherstrasse, Basel, CH 4070,Switzerland
Keywords: Anti-cancer drugs, EMA, embryotoxicity, FDA, nonclinical safety testing, reproductive toxicity, teratogenicity.
Abstract: This paper reviews the nonclinical reproductive toxicity testing of 15 drugs currently approved in the USA or Europe for the treatment of cancer. The list includes cytotoxic anti-tumour agents, small molecule inhibitors of pathways involved in neoplastic proliferation, monoclonal antibodies that target specific antigens expressed by neoplastic cells and supportive therapies used to counter the effects of chemotherapy. Most, but not all, drugs were tested for developmental or reproductive toxicity in animals prior to marketing and most were found to be embryotoxic or teratogenic. Because of the unmet need for comparative safety data on available cancer therapies for use by physicians when treating pregnant patients, at least embryofetal toxicity studies are now usually requested prior to marketing of new anti-cancer drugs, even when the pharmacological profile suggests likely side-effects on the embryo or fetus. Rats and rabbits are the preferred experimental species, but non-human primates have to be used for some biopharmaceuticals. Nonclinical study designs for anti-cancer drugs should be designed to allow the possibility of terminating the study once adverse effects have been demonstrated, without using the full number of animals specified in regulatory guidelines. All 15 drugs are currently labelled as being harmful to pregnancy, ether on the basis of animal data or documented hazards in humans. It is hoped that the forthcoming revision of the FDA drug labelling legislation will allow a better graduation of the relative risk between available anti-cancer therapies.
Export Options
About this article
Cite this article as:
Barrow Paul*, Schmitt Georg, Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (9) . https://dx.doi.org/10.2174/1871520616666160613122702
DOI https://dx.doi.org/10.2174/1871520616666160613122702 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor metastasis ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Metalloenzymes and Cancer: Μetalloenzyme Ιnhibitors and Artificial Metalloenzymes as anti-cancer agents
Metalloenzymes are enzymes containing metal ions, which are directly bound to the enzyme and play a role in promoting catalysis. About one-third of all enzymes known so far are metalloenzymes [1]. Metalloenzymes are central to a wide range of essential biological activities, including nucleic acid modification, protein degradation, and many ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Prostaglandin Agonist Beraprost Aggravates Doxorubicin-mediated Apoptosis by Increasing iNOS Expression in Cardiomyocytes
Current Vascular Pharmacology Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Monoamine Receptors in the Regulation of Feeding Behaviour and Energy Balance
CNS & Neurological Disorders - Drug Targets Natural Bioactive Compounds against Oxidative Stress: Dietary Polyphenols Strike Back
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Differences in the Fat Attenuation Index Ratio of Pericoronary Adipose Tissue And Aortic Root Epicardial Adipose Tissue in Various Plaques
Current Medical Imaging Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Mitochondrially Targeted Antioxidants for the Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Glucocorticoid Analogues: Potential Therapeutic Alternatives for Treating Inflammatory Muscle Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Immunomodulatory Therapeutic Effects of Curcumin on M1/M2 Macrophage Polarization in Inflammatory Diseases
Current Molecular Pharmacology Curcumin and Curcumin Derivatives for Therapeutic Applications: <i>In vitro</i> and <i>In vivo</i> Studies
Current Nutrition & Food Science Ryanodine Receptors for Drugs and Insecticides: An Overview
Mini-Reviews in Medicinal Chemistry